Synopsis
Synopsis
0
EU WC
0
VMF
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Apo Misoprostol
2. Apo-misoprostol
3. Cytotec
4. Glefos
5. Misoprostol, (11alpha,13e)-isomer
6. Misoprostol, (11alpha,13e,16r)-isomer
7. Misoprostol, (11alpha,13z)-(+-)-isomer
8. Misoprostol, (11alpha.13e,16s)-isomer
9. Misoprostol, (11beta,13e)-(+-)-isomer
10. Misoprostol, (11beta,13e,16r)-isomer
11. Misoprostol, (11beta,13e,16s)-isomer
12. Novo Misoprostol
13. Novo-misoprostol
14. Sc 29333
15. Sc 30249
16. Sc-29333
17. Sc-30249
18. Sc29333
19. Sc30249
1. 59122-46-2
2. Cytotec
3. Isprelor
4. Sc-29333
5. Misoprostolum [inn-latin]
6. Misodel
7. Sc 29333
8. Ccris 6859
9. Hsdb 3573
10. Methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate
11. Brn 4155643
12. 103601-27-0
13. 0e43v0bb57
14. Prost-13-en-1-oic Acid, 11,16-dihydroxy-16-methyl-9-oxo-, Methyl Ester,(11a,13e)-
15. Ncgc00162445-02
16. Misoprostolum
17. Misoprost
18. Misotol
19. Misogon
20. Misopess
21. Misotac
22. Gymiso
23. Methyl (11alpha,13e)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate
24. 7-[(1r,2r,3r)-3-hydroxy-2-[(e)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoic Acid Methyl Ester
25. Cytotec (tn)
26. Misoprostol (methyl Ester)
27. Sr-01000695425
28. Unii-0e43v0bb57
29. Xp-16j
30. Mvi 200
31. Methyl 7-((1r,2r,3r)-3-hydroxy-2-((e)-4-hydroxy-4-methyloct-1-enyl)-5-oxocyclopentyl)heptanoate
32. 11
33. A-misoprostol
34. Cas_59122-46-2
35. Misoprostol [usan:usp:inn:ban:jan]
36. Misoprostol [mi]
37. Dsstox_cid_897
38. Misoprostol [inn]
39. Misoprostol [jan]
40. Methyl (+-)-11-alpha,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate
41. Misoprostol [hsdb]
42. Misoprostol [usan]
43. Chembl606
44. Misoprostol [vandf]
45. Schembl7787
46. (11-alpha,13e)-(+-)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oic Acid Methyl Ester
47. Dsstox_rid_75852
48. Misoprostol [mart.]
49. Dsstox_gsid_20897
50. Misoprostol [usp-rs]
51. Misoprostol [who-dd]
52. Mls000028863
53. Misoprostol (jan/usp/inn)
54. Misoprostol, 1% In Cellulose
55. Gtpl1936
56. Dtxsid7020897
57. Bdbm85606
58. Chebi:94387
59. Misoprostol, >=99% (hplc)
60. Misoprostol [orange Book]
61. Regid_for_cid_5282381
62. Hms2090l10
63. Hms3648f03
64. Hms3715k08
65. Misoprostol [ep Monograph]
66. Misoprostol [usp Monograph]
67. Ex-a1774
68. Hy-b0610
69. Tox21_112010
70. Arthrotec Component Misoprostol
71. Akos015899652
72. Ccg-221093
73. Db00929
74. Prost-13-en-1-oic Acid, 11,16-dihydroxy-16-methyl-9-oxo-, Methyl Ester, (11alpha,13e)-
75. Smp1_000193
76. Misoprostol Component Of Arthrotec
77. Ncgc00162445-01
78. Ncgc00162445-03
79. (+-)-methyl (1r,2r,3r)-3-hydroxy-2-((e)-(4rs)-4-hydroxy-4-methyl-1-octenyl)-5-oxocyclopentaneheptanoate
80. 62015-39-8
81. As-83017
82. Smr000058558
83. Cas-59122-46-2
84. D00419
85. Ab00513745-05
86. 122m462
87. A832173
88. Q416025
89. Q-201409
90. Sr-01000695425-2
91. Sr-01000695425-4
92. Brd-a50310035-001-01-6
93. Misoprostol, European Pharmacopoeia (ep) Reference Standard
94. Misoprostol, United States Pharmacopeia (usp) Reference Standard
95. (+/-) Methyl 11alpha, 16-dihydroxy-16-methyl-9-oxoprost-13e-en-1-oate
96. (+/-) Methyl 11alpha,16-dihydroxy-16-methyl-9-oxoprost-13e-en-1-oate
97. (+/-) Methyl-11alpha,16-dihydroxy-16-methyl-9-oxoprost-13e-en-1-oate
98. (+/-) Methyl-11alpha,16-dihydroxy-16-methyl-9-oxoprost13e-en-1-oate
99. (+/-)-(11a,13e)-11,16-dihydroxy-16-methyl-9-oxo-prost-13-en-1-oic Acid Methyl Ester
100. (11alpha,13e)-11,16-dihydroxy-16-methyl-9-oxoprosta-13-ene-1-oic Acid Methyl Ester
101. 9-oxo-11alpha,16-dihydroxy-16-methyl-prost-13e-en-1-oic Acid, Methyl Ester
102. Misoprostol For System Suitability, European Pharmacopoeia (ep) Reference Standard
103. (+/-)-methyl (1r,2r,3r)-3-hydroxy-2-((e)-(4rs)-4-hydroxy-4-methyl-1-octenyl)-5-oxocyclopentaneheptanoate
104. Methyl 7-[(1r,2r,3r)-2-[(e)-4-methyl-4-oxidanyl-oct-1-enyl]-3-oxidanyl-5-oxidanylidene-cyclopentyl]heptanoate
105. Methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate
106. Prost-13-en-1-oic Acid, 11,16-dihydroxy-16-methyl-9-oxo-, Methyl Ester, (11.alpha.,13e)-(+/-)-
107. Prost-13-en-1-oic Acid, 11,16-dihydroxy-16-methyl-9-oxo-, Methyl Ester, (11alpha,13e)-(+-)-
108. Rel-methyl 7-((1r,2r,3r)-3-hydroxy-2-((e)-4-hydroxy-4-methyloct-1-en-1-yl)-5-oxocyclopentyl)heptanoate
| Molecular Weight | 382.5 g/mol |
|---|---|
| Molecular Formula | C22H38O5 |
| XLogP3 | 3.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 14 |
| Exact Mass | 382.27192431 g/mol |
| Monoisotopic Mass | 382.27192431 g/mol |
| Topological Polar Surface Area | 83.8 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 487 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Cytotec |
| PubMed Health | Misoprostol (By mouth) |
| Drug Classes | Antiulcer, Protectant, Endocrine-Metabolic Agent |
| Drug Label | Misoprostol oral tablets contain either 100 mcg or 200 mcg of misoprostol, a synthetic prostaglandin E1 analog.Misoprostol contains approximately equal amounts of the two diastereomers presented below with their enantiomers indicated by ():Misopros... |
| Active Ingredient | Misoprostol |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 0.2mg; 0.1mg |
| Market Status | Prescription |
| Company | Gd Searle |
| 2 of 4 | |
|---|---|
| Drug Name | Misoprostol |
| PubMed Health | Misoprostol (By mouth) |
| Drug Classes | Antiulcer, Protectant, Endocrine-Metabolic Agent |
| Drug Label | Misoprostol oral tablets contain either 100 mcg or 200 mcg of misoprostol, a synthetic prostaglandin E1 analog.Misoprostol contains approximately equal amounts of the two diastereomers presented below with their enantiomers indicated by ():Misopros... |
| Active Ingredient | Misoprostol |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 0.1mg; 0.2mg |
| Market Status | Prescription |
| Company | Novel Labs; Ivax Sub Teva Pharms |
| 3 of 4 | |
|---|---|
| Drug Name | Cytotec |
| PubMed Health | Misoprostol (By mouth) |
| Drug Classes | Antiulcer, Protectant, Endocrine-Metabolic Agent |
| Drug Label | Misoprostol oral tablets contain either 100 mcg or 200 mcg of misoprostol, a synthetic prostaglandin E1 analog.Misoprostol contains approximately equal amounts of the two diastereomers presented below with their enantiomers indicated by ():Misopros... |
| Active Ingredient | Misoprostol |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 0.2mg; 0.1mg |
| Market Status | Prescription |
| Company | Gd Searle |
| 4 of 4 | |
|---|---|
| Drug Name | Misoprostol |
| PubMed Health | Misoprostol (By mouth) |
| Drug Classes | Antiulcer, Protectant, Endocrine-Metabolic Agent |
| Drug Label | Misoprostol oral tablets contain either 100 mcg or 200 mcg of misoprostol, a synthetic prostaglandin E1 analog.Misoprostol contains approximately equal amounts of the two diastereomers presented below with their enantiomers indicated by ():Misopros... |
| Active Ingredient | Misoprostol |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 0.1mg; 0.2mg |
| Market Status | Prescription |
| Company | Novel Labs; Ivax Sub Teva Pharms |
Abortifacient Agents, Nonsteroidal; Anti-Ulcer Agents; Oxytocics
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Misoprostol is indicated for the prevention of gastric ulcer associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, in patients at high risk of complications from gastric ulcer, such as the elderly, and in patients with concomitant disease or patients at high risk of developing gastric ulceration, such as those with a history of ulcer. /Included in US product labeling/
USP Convention. USPDI - Drug Information for the Health Care Professional. 16th ed. Volume I. Rockville, MD: U.S. Pharmaceutical Convention, Inc. 1996 (Plus updates)., p. 2085
Misoprostol is indicated in the short-term treatment of duodenal ulcer. /NOT included in US product labeling/
USP Convention. USPDI - Drug Information for the Health Care Professional. 16th ed. Volume I. Rockville, MD: U.S. Pharmaceutical Convention, Inc. 1996 (Plus updates)., p. 2085
The efficacy and tolerability of mifepristone in combo with misoprostol for termination of early pregnancy (up to 49 days of amenorrhea) are established.
PMID:8574255 Aub'eny E et al; Int J Fertil Menopausal Stud 40 (Suppl 2): 85-91 (1995)
For more Therapeutic Uses (Complete) data for MISOPROSTOL (8 total), please visit the HSDB record page.
Misoprostol is contraindicated during pregnancy. Studies in humans have shown that misoprostol causes an increase in the frequency and intensity of uterine contractions. Misoprostol administration has also been associated with a higher incidence of uterine bleeding and expulsion of uterine contents. Miscarriages caused by misoprostol are likely to be incomplete, resulting in very serious medical complications, sometimes requiring hospitalization and surgery, and possibly causing infertility.
USP Convention. USPDI - Drug Information for the Health Care Professional. 16th ed. Volume I. Rockville, MD: U.S. Pharmaceutical Convention, Inc. 1996 (Plus updates)., p. 2086
Patients of childbearing potential may use misoprostol if nonsteroidal anti-inflammatory drug (NSAID) therapy is required and patient is at high risk of complications from gastric ulcers associated with the use of NSAIDs, or is at high risk of developing gastric ulceration. Such patients must comply with effective contraceptive measures, must have had a negative serum pregnancy test within 2 weeks prior to initiation of therapy and must start misoprostol therapy only on the second or third day of the next normal menstrual period.
USP Convention. USPDI - Drug Information for the Health Care Professional. 16th ed. Volume I. Rockville, MD: U.S. Pharmaceutical Convention, Inc. 1996 (Plus updates)., p. 2086
It is unlikely that misoprostol is distributed into breast milk since it is rapidly metabolized throughout the body. however, it is not known if the active metabolite, misoprostol acid, is distributed into breast milk. Therefore, administration of misoprostol to nursing women is not recommended because of the potential distribution of misoprostol acid, which could cause significant diarrhea in the nursing infant.
USP Convention. USPDI - Drug Information for the Health Care Professional. 16th ed. Volume I. Rockville, MD: U.S. Pharmaceutical Convention, Inc. 1996 (Plus updates)., p. 2086
Misoprostol generally is well tolerated. The frequency of adverse effects does not appear to be affected by patient age in adults. The most frequent adverse effects associated with misoprostol therapy involve the GI tract (e.g., diarrhea, nausea, abdominal pain).
McEvoy G.K. (ed.). American Hospital Formulary Service-Drug Information 96. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1996 (Plus Supplements)., p. 2169
For more Drug Warnings (Complete) data for MISOPROSTOL (8 total), please visit the HSDB record page.
Misoprostol is indicated as a tablet to reduce the risk of NSAID induced gastric ulcers but not duodenal ulcers in high risk patients. Misoprostol is also formulated in combination with diclofenac to treat symptoms of osteoarthritis or rheumatoid arthritis in patients with a high risk of developing gastric ulcers. Misoprostol is used off label for the management of miscarriages, prevention of post partum hemorrhage, and is also used alone or in combination with mifepristone in other countries for first trimester abortions.
FDA Label
Induction of labour
Induction of labour
Misoprostol is a prostaglandin E1 analog used to reduce the risk of NSAID induced gastric ulcers by reducing secretion of gastric acid from parietal cells. Misoprostol is also used to manage miscarriages and used alone or in combination with mifepristone for first trimester abortions. An oral dose of misoprostol has an 8 minute onset of action and a duration of action of approximately 2 hours, a sublingual dose has an 11 minute onset of action and a duration of action of approximately 3 hours, a vaginal dose has a 20 minute onset of action and a duration of action of approximately 4 hours, and a rectal dose has a 100 minute onset of action and a duration of action of approximately 4 hours.
Oxytocics
Drugs that stimulate contraction of the myometrium. They are
Market Place
